Evidence map›Paper›PMID 42797333›Full record

ArticlePharmaceutics2026

Developing a Fluorescence-Based High-Throughput Screening Method for Natural Product Fractions to Identify Inhibitors of AR-V7 for Castration-Resistant Prostate Cancer.

Neha Tyagi, Manish Rathi, Susan Ensel, Christopher C Thornburg, Tanja Grkovic, Barry R O'Keefe, James C Sacchettini, Chendil Damodaran

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Neha TyagiDepartment of Pharmaceutical Sciences, Texas A&M University, College Station, TX 77843, USA.
Manish RathiDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA.ORCID 0009-0002-9232-2498
Susan EnselNatural Products Support Group, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0002-7733-1065
Christopher C ThornburgNatural Products Support Group, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.ORCID 0000-0002-4657-6895
Tanja GrkovicNatural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0002-6537-3997
Barry R O'KeefeNatural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, MD 21702, USA.ORCID 0000-0003-0772-4856
James C SacchettiniDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843, USA.ORCID 0000-0001-5767-2367
Chendil DamodaranDepartment of Pharmaceutical Sciences, Texas A&M University, College Station, TX 77843, USA.ORCID 0000-0002-9902-7101

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
CCR NIH HHS HHSN261200800001CNCI NIH HHS UG3CA290353NIH HHS 75N91019D00024NIH HHS HHSN261200800001ETexas A&M University 291007-23006Welch Foundation Grant No. A-0015 (to J.C.S.)
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

androgen receptorAR-V7butanolidescastration-resistant prostate cancerHiBiT reporterhigh-throughput screeningnatural products

Identifiers

PMID42797333
PMCPMC13610743

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.